Table 4. Association of Clopidogrel vs Ticagrelor With Outcomes Within 1 Year After Percutaneous Coronary Intervention for Acute Coronary Syndrome in Propensity Score–Matched Cohort.
| Outcome | No. (%) | P Value | HR (95% CI) | |
|---|---|---|---|---|
| Clopidogrel Group (n = 3711) | Ticagrelor Group (n = 3711) | |||
| MACE | 368 (9.9) | 380 (10.2) | .64 | 1.00 (0.86-1.17) |
| All-cause death | 54 (1.5) | 61 (1.6) | .51 | 1.10 (0.75-1.61) |
| ACS | 228 (6.1) | 235 (6.3) | .74 | 1.02 (0.84-1.24) |
| Coronary revascularization | 168 (4.5) | 157 (4.2) | .53 | 0.86 (0.67-1.09) |
| PCI | 121 (3.3) | 114 (3.1) | .64 | 0.90 (0.68-1.19) |
| CABG | 50 (1.3) | 44 (1.2) | .53 | 0.74 (0.47-1.15) |
| Stent thrombosis | 7 (0.2) | 18 (0.5) | .03 | 2.57 (1.07-6.16)a |
| Composite of all-cause death, ACS, or stroke | 290 (7.8) | 299 (8.1) | .70 | 1.02 (0.86-1.21) |
| Ischemic stroke | 18 (0.5) | 17 (0.5) | .87 | 0.94 (0.48-1.86) |
| Major bleed | 182 (4.9) | 261 (7.0) | <.001 | 1.52 (1.24-1.87)a |
| Intracranial | 3 (0.1) | 3 (0.1) | >.99 | 1.00 (0.14-7.10) |
| Gastrointestinal | 53 (1.4) | 95 (2.6) | <.001 | 2.10 (1.44-3.06)a |
| Pulmonary | 81 (2.2) | 105 (2.8) | .08 | 1.32 (0.97-1.80) |
| Urologic | 29 (0.8) | 37 (1.0) | .32 | 1.32 (0.79-2.22) |
| Other | 32 (0.9) | 38 (1.0) | .47 | 1.29 (0.78-2.11) |
| Dyspnea | 46 (1.2) | 116 (3.1) | <.001 | 2.42 (1.70-3.45)a |
Abbreviations: ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; HR, hazard ratio; MACE, major adverse coronary event; PCI, percutaneous coronary intervention.
a
Statistically significant results.